Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy
Fujiwara, H.; Hamaoka, T.
Progress in Experimental Tumor Research 32: 69-103
1988
ISSN/ISBN: 0079-6263 PMID: 2967523 DOI: 10.1159/000414674
Accession: 039485255
PDF emailed within 0-6 h: $19.90
Related References
Ting, C.C.; Rodrigues, D.; Nordan, R. 1982: Studies of the mechanisms for the induction of in vivo tumor immunity. VI. Induction of specific and nonspecific cell-mediated immunity in tumor-bearing hosts and its correlation with transplantation tumor immunity Cellular Immunology 66(1): 45-58Hamaoka, T.; Kosugi, A.; Shima, J.; Sato, S.; Sano, H.; Takai, Y.; Fujiwara, H. 1988: T t cell interaction for the augmented induction of anti tumor protective immunity and its application to active immunotherapy in tumor bearing hosts Hashimoto, Y And T Hamaoka (Ed ) Gann Monograph on Cancer Research, No 34 Cellular And Molecular Mechanisms Of Tumor Immunity Viii+194p Japan Scientific (Societies) Press: Tokyo, Japan; Taylor And Francis Ltd : Philadelphia, Pennsylvania, Usa; London, England, Uk Illus 81-90
Fujisawa, Y.; Nabekura, T.; Nakao, T.; Nakamura, Y.; Takahashi, T.; Kawachi, Y.; Otsuka, F.; Onodera, M. 2009: The induction of tumor-specific CD4+ T cells via major histocompatibility complex class Ii is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells Experimental Dermatology 18(4): 396-403
Udono, H.; Levey, D.L.; Srivastava, P.K. 1994: Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo Proceedings of the National Academy of Sciences of the United States of America 91(8): 3077-3081
Yoshioka, T.; Fukuzawa, M.; Takai, Y.; Wakamiya, N.; Ueda, S.; Kato, S.; Fujiwara, H.; Hamaoka, T. 1986: The augmentation of tumor-specific immunity by virus help. III: enhanced generation of tumor-specific Lyt-1+2-T cells is reponsible for augmented tumor immunity in vivo Cancer Immunology and ImmunoTherapy 21(3): 193-198
Yoshioka, T.; Fukuzawa, M.; Takai, Y.; Wakamiya, N.; Ueda, S.; Kato, S.; Fujiwara, H.; Hamaoka, T. 1986: The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo Cancer Immunology Immunotherapy: Cii 21(3): 193-198
Sano, S.; Izumi, Y.; Sugihara, S.; Nakajima, H.; Fujiwara, H.; Hamaoka, T. 1987: The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens Cancer Immunology Immunotherapy: Cii 25(2): 105-110
Izumi, Y.; Tsuchida, T.; Okuno, K.; Fujiwara, H.; Hamaoka, T. 1985: Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1 Japanese Journal of Cancer Research: Gann 76(9): 863-870
Büeler, H.; Mulligan, R.C. 1996: Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1 Molecular Medicine 2(5): 545-555
Inamoto, T.; Kan, N.; Ohgaki, K.; Hikasa, Y. 1983: Different immunosuppression on specific anti-tumor and non-specific cellular immunity of tumor-bearing mice following tumor growth Nihon Geka Hokan. Archiv für Japanische Chirurgie 52(2): 196-206
Bendre, A.R.; Gangal, S.G. 1978: Use of vaccinia virus as an adjuvant in inducing specific anti tumor immunity to transplantable mouse fibro sarcoma 2. rejection of tumor graft in vivo humoral and lymphocyto toxicity in vitro Indian Journal of Cancer 15(4): 9-16
Hamaoka, T.; Shimizu, J.; Suda, T.; Fujiwara, H. 1988: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells Princess Takamatsu Symposia 19: 265-275
Shimizu, J.; Suda, T.; Yoshioka, T.; Kosugi, A.; Fujiwara, H.; Hamaoka, T. 1989: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells Journal of Immunology 142(3): 1053-1059
Shimizu, J.; Suda, T.; Yoshioka, T.; Kosugi, A.; Fujiwara, H.; Hamaoka, T. 1989: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells The Journal of Immunology (1950) 142(3): 1053-1059
Bosslet, K.; Schirrmacher, V.; Shantz, G. 1979: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro International Journal of Cancer 24(3): 303-313
Dan, Q.; Williams, C.C.; Jeffes, E.W.B.; Morgan, T.R.; Wepsic, H.T.; Douglass, T.; Jadus, M.R. 2000: Tumor cells expressing membrane macrophage colony stimulating factor leads to in vivo tumor rejection and immunity against the parental tumor cells Lessons learned from three different tumor models Cancer Gene Therapy 7(12): S22-S23
Binz, H.; Meier, B.; Wigzell, H. 1982: Induction or elimination of tumor-specific immunity against a chemically-induced rat tumor using auto-anti-idiotypic immunity International Journal of Cancer 29(4): 417-423
Lillehei, K.O.; Liu, Y.; Kong, Q.Z.; Ng, K.Y. 1999: Examination of the time course for the development of anti-tumor immunity using active-specific immunotherapy in the rat 9L glioma tumor model Proceedings of the American Association for Cancer Research Annual Meeting 40: 252
Hanna, M.G.; Bucana, C. 1979: Active specific immunotherapy of residual micrometastasis: the acute and chronic inflammatory response in induction of tumor immunity by BCG-tumor cell immunization Journal of the Reticuloendothelial Society 26(4): 439-451
Takeda, Y.; Yoshida, S.; Takashima, K.; Ishii-Mugikura, N.; Shime, H.; Seya, T.; Matsumoto, M. 2018: Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models Cancer Science 109(7): 2119-2129